glp 1 receptor in brain Insights into a possible role of glucagon-like peptide-1 agonists the treatment of depression | Pharmacological Reports GLP-1 drugs protect brain health

The two biggest ongoing trials are TRIUMPH-1 (2,300 people with obesity) and TRIUMPH-2 (1,000 people with type 2 diabetes and obesity)

GIP and GLP-1 receptor antagonism during a meal in healthy individuals

In contrast, modern GLP-1 receptor agonists and dual incretin agonists have demonstrated clinically meaningful and sustained reductions in body weight, with additional benefits on glycemic control and cardiometabolic risk markers

After dehydrated and xylene incubation, the sections were assembled with Depex, covered with coverslips and dried o/n

however, these benefits were limited only to obese patients (99)